Clinical Cardiology (Hoboken) 2008-03-01

Update on atrial fibrillation: part II.

Irina Savelieva, John Camm

Index: Clin. Cardiol. 31(3) , 102-8, (2008)

Full Text: HTML

Abstract

Antiarrhythmic drugs are an essential tool in the management of atrial fibrillation (AF). Although we are already on the threshold of a large expansion in the use of ablation therapies, these will not, however, be appropriate for all patients, and pharmacological therapies will continue to have an important place in the management of atrial fibrillation. The plethora of antiarrhythmic drugs currently available for the treatment of atrial fibrillation is a reflection that none is wholly satisfactory, each having limited efficacy combined with poor safety and tolerability. Improved class III antiarrhythmic drugs, such as dronedarone, new classes of antiarrhythmic agents, such as atrial repolarization delaying agents, and upstream therapies dealing with substrate, represent potential sources of new pharmacological therapies.

Related Compounds

  • Azimilide (Dihydr...

Related Articles:

Azimilide dihydrochloride: a new class III anti-arrhythmic agent.

2000-11-01

[Expert Opin. Investig. Drugs 9(11) , 2705-15, (2000)]

Electrophysiological and antiarrhythmic effects of the novel antiarrhythmic agent AZD7009: a comparison with azimilide and AVE0118 in the acutely dilated right atrium of the rabbit in vitro.

2006-07-01

[Europace 8(7) , 549-57, (2006)]

Azimilide for the treatment of atrial fibrillation, atrial flutter, and paroxysmal supraventricular tachycardia: results of a randomized trial and insights on the concordance of symptoms and recurrent arrhythmias.

2008-02-01

[J. Cardiovasc. Electrophysiol. 19(2) , 172-7, (2008)]

Role of drug therapy for sustained ventricular tachyarrhythmias.

2008-08-01

[Cardiol. Clin. 26(3) , 405-18, vi, (2008)]

Effects of azimilide on the muscarinic acetylcholine receptor-operated K+ current and experimental atrial fibrillation in guinea-pig hearts.

2007-11-01

[J. Pharmacol. Sci. 105(3) , 229-39, (2007)]

More Articles...